title: Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient.
abstract: Cardiovascular disease is the most common cause of sickness and death for long-term kidney transplant recipients, and dyslipidemia is an important risk factor for developing cardiovascular disease. Lipid-lowering strategies, with the use of statins, have been shown to reduce the cardiovascular risks related to dyslipidemia, but concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and immunosuppressive agents may increase the risk of rhabdomyolysis owing to a drug-drug interaction. We report a case of simvastatin-induced rhabdomyolysis and acute kidney injury triggered by addition of sirolimus and cisplatin-based chemotherapy to a kidney transplant recipient who had previously tolerated chronic statin therapy.
authors.affiliation: From the Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Yu Ah
authors.initials: YA
authors.lastname: Hong
authors.forename: Hyung Duk
authors.initials: HD
authors.lastname: Kim
authors.forename: Kwanhoon
authors.initials: K
authors.lastname: Jo
authors.forename: Yun Kyung
authors.initials: YK
authors.lastname: Park
authors.forename: Jonghoon
authors.initials: J
authors.lastname: Lee
authors.forename: In O
authors.initials: IO
authors.lastname: Sun
authors.forename: Byung Ha
authors.initials: BH
authors.lastname: Chung
authors.forename: Cheol Whee
authors.initials: CW
authors.lastname: Park
authors.forename: Chul Woo
authors.initials: CW
authors.lastname: Yang
authors.forename: Bum Soon
authors.initials: BS
authors.lastname: Choi
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D004347:Drug Interactions; D050171:Dyslipidemias / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D006435:Renal Dialysis; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D012307:Risk Factors; D012720:Severity of Illness Index; D019821:Simvastatin / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D019821:Simvastatin; D002945:Cisplatin; D020123:Sirolimus